Capital Medica Ventures

Capital Medica Ventures (CMV) is a venture capital firm based in Tokyo, Japan, focusing on early-stage investments within the healthcare sector. Established in 2016, CMV emphasizes impact investing, targeting startups that address significant social challenges related to healthcare and wellness. Its mission is to be a supportive partner, guiding entrepreneurs who are driving change through innovative solutions. CMV operates several funds, including the "Healthcare New Frontier Fund," which invests in companies with the potential to create substantial outcomes for customers by improving their health and quality of life. The firm’s investment approach is deeply rooted in Impact Management and Measurement (IMM), which ensures that financial support is aligned with generating measurable social impact. CMV typically invests between ¥5 million to several hundred million yen per round, with follow-on funding based on the startup’s growth trajectory. Notable portfolio companies include Emimen, which recently achieved an IPO on the Tokyo Stock Exchange’s growth market, showcasing CMV's ability to nurture and scale promising ventures. CMV manages a variety of specialized funds, such as the Tokyo Wellness Impact Fund, which supports startups in wellness across sectors like healthcare, elderly care, and fitness. Additionally, the firm collaborates with other institutions like Nanto Bank to expand its reach into regional projects through the Yamato Social Impact Fund, focusing on broader areas such as agriculture, education, and cultural preservation. Led by CEO Takeshi Aoki, CMV combines strategic expertise with a commitment to sustainable, impact-driven growth, positioning itself as a leader in Japan’s healthcare venture capital space.